Compare JMM & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMM | KRRO |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 58.6M |
| IPO Year | N/A | 2019 |
| Metric | JMM | KRRO |
|---|---|---|
| Price | $6.15 | $5.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | 16.1K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,371,000.00 |
| Revenue This Year | N/A | $116.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.29 | $5.20 |
| 52 Week High | $6.10 | $55.89 |
| Indicator | JMM | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 22.32 |
| Support Level | $6.06 | $5.20 |
| Resistance Level | $6.16 | $6.59 |
| Average True Range (ATR) | 0.04 | 0.51 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 64.29 | 24.31 |
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.